Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
2
50%
Ph phase_1
2
50%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Not yet recruiting2
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

not_yet_recruiting250%
active_not_recruiting125%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
not_yet_recruitingphase_3

A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography

NCT07740421
active_not_recruitingphase_3

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

NCT06815627
not_yet_recruitingphase_1

NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer

NCT07314385
completedphase_1

A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

NCT04185246

Clinical Trials (4)

Showing 4 of 4 trials
NCT07740421Phase 3

A Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intravenous Bolus Injection and Infusion for Subjects Undergoing Cardiac Echocardiography

Not Yet Recruiting
NCT06815627Phase 3

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

Active Not Recruiting
NCT07314385Phase 1

NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer

Not Yet Recruiting
NCT04185246Phase 1

A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4